# An Open-Label Study to Assess the Effect of CYP3A4 Induction on the Pharmacokinetics of VELCADE (Bortezomib)

> **NCT00608907** · PHASE1 · COMPLETED · sponsor: **Millennium Pharmaceuticals, Inc.** · enrollment: 61 (actual)

## Conditions studied

- Multiple Myeloma
- Non-Hodgkin's Lymphoma

## Interventions

- **DRUG:** bortezomib
- **DRUG:** bortezomib, rifampicin
- **DRUG:** bortezomib, dexamethasone

## Key facts

- **NCT ID:** NCT00608907
- **Lead sponsor:** Millennium Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-09
- **Primary completion:** 2010-03
- **Final completion:** 2010-04
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2012-01-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00608907

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00608907, "An Open-Label Study to Assess the Effect of CYP3A4 Induction on the Pharmacokinetics of VELCADE (Bortezomib)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00608907. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*